{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:06Z","timestamp":1787019546552,"version":"build-2736575974"},"reference-count":51,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Viral infections are important causes of morbidity and mortality for patients with a hematological malignancy. However, the true incidence and consequences of viral infections for these patients who undergo conventional nontransplant therapy are poorly defined. The difference in incidence and outcome of viral infections among patient groups is wide, but dependent upon the intensity and duration of T-cell\u2013mediated immune suppression. Infections caused by cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV), respiratory syncytial virus (RSV), parainfluenza viruses and influenza viruses have been intensely studied, yet newly recognized aspects of these viral infections including late CMV infection; the emergence of new viral pathogens (human herpesvirus-6, BK virus, adenovirus, and human metapneumovirus); the development of molecular diagnostic techniques, and the potential of new agents for viral prophylaxis (maribavir), or preemptive therapy (valganciclovir) form the basis of this review. Well-designed prospective studies are needed to better clarify the spectrum of these viral infections and develop effective prevention and treatment strategies. Yet the increased use of agents like alemtuzumab that induce profound T-cell depletion demands that we develop a better understanding of viral infections that occur in patients with hematological malignancy who receive nontransplant therapy.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.368","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T18:14:02Z","timestamp":1164219242000},"page":"368-374","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Viral Infections in Patients with Hematological Malignancies"],"prefix":"10.1182","volume":"2006","author":[{"given":"James C.","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702205070300_R1","doi-asserted-by":"crossref","unstructured":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients; recommendations of the CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2000;6:659\u2013734.","DOI":"10.1016\/S1083-8791(00)70002-4"},{"key":"2019111702205070300_R2","doi-asserted-by":"crossref","unstructured":"Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am. 1993;7:293\u2013315.","DOI":"10.1016\/S0889-8588(18)30268-5"},{"key":"2019111702205070300_R3","doi-asserted-by":"crossref","unstructured":"Lungman P. Viral Infections: current diagnosis and treatment. Hematology J. 2004;5:S63\u2013S68.","DOI":"10.1038\/sj.thj.6200425"},{"key":"2019111702205070300_R4","doi-asserted-by":"crossref","unstructured":"Sandherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Disease Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol. 2006;17:1051\u20131059.","DOI":"10.1093\/annonc\/mdj132"},{"key":"2019111702205070300_R5","doi-asserted-by":"crossref","unstructured":"Boeckh M, Erard V, Zerr D, et al. Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant. 2005;9:48\u201354.","DOI":"10.1111\/j.1399-3046.2005.00442.x"},{"key":"2019111702205070300_R6","doi-asserted-by":"crossref","unstructured":"Anaissie EJ, Kontoyiannis DP, O\u2019Brien S, et al. Infections in patients with Chronic Lymphocytic Leukemia treated with Fludarabine. Ann Intern Med. 1998;129:559\u2013566.","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"key":"2019111702205070300_R7","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Pillay D, Ratcliffe D, et al. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis. 2000;181:2055\u20132058.","DOI":"10.1086\/315524"},{"key":"2019111702205070300_R8","doi-asserted-by":"crossref","unstructured":"Locksley RM, Flournoy N, Sullivan KM, et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172\u20131181.","DOI":"10.1093\/infdis\/152.6.1172"},{"key":"2019111702205070300_R9","unstructured":"Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003;9:976\u2013980."},{"key":"2019111702205070300_R10","doi-asserted-by":"crossref","unstructured":"Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol. 2004;25:603\u2013608.","DOI":"10.1086\/502447"},{"key":"2019111702205070300_R11","doi-asserted-by":"crossref","unstructured":"David DS, Tegtmeier BR, O\u2019Donnell MR, et al. Visceral varicella-zoster virus after bone marrow transplantation: report and review of the literature. Am J Gastroenterol. 1998;93:810\u2013813.","DOI":"10.1111\/j.1572-0241.1998.230_a.x"},{"key":"2019111702205070300_R12","doi-asserted-by":"crossref","unstructured":"Boeckh M, Kim HW, Flowers ED, et al. Long-term acyclovir for prevention of varicella zoster virus disease after hematopoietic cell transplantation \u2013 a double-blind placebo-controlled study. Blood. 2006;107:1800\u20131805.","DOI":"10.1182\/blood-2005-09-3624"},{"key":"2019111702205070300_R13","doi-asserted-by":"crossref","unstructured":"Boeckh M, Garret WG, Papanicolau G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges and future strategies. Biol Blood Marrow Transplant. 2003;9:543\u2013558.","DOI":"10.1016\/S1083-8791(03)00287-8"},{"key":"2019111702205070300_R14","doi-asserted-by":"crossref","unstructured":"Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Human Immunology. 2004;65:432\u2013436.","DOI":"10.1016\/j.humimm.2004.02.022"},{"key":"2019111702205070300_R15","doi-asserted-by":"crossref","unstructured":"Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath\u20131H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002;3:105\u2013110.","DOI":"10.3816\/CLM.2002.n.016"},{"key":"2019111702205070300_R16","doi-asserted-by":"crossref","unstructured":"Faderl S, Thomas DA, O\u2019Brien S, et al. Experience with alemtuzumab plus Rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413\u20133415.","DOI":"10.1182\/blood-2002-07-1952"},{"key":"2019111702205070300_R17","doi-asserted-by":"crossref","unstructured":"Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003\u20132008.","DOI":"10.1182\/blood-2003-10-3616"},{"key":"2019111702205070300_R18","doi-asserted-by":"crossref","unstructured":"Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood2002; 99:1978\u20131985.","DOI":"10.1182\/blood.V99.6.1978"},{"key":"2019111702205070300_R19","doi-asserted-by":"crossref","unstructured":"Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD 34\u2013selected peripheral blood stem cell transplantation. Blood. 1999;94:4029\u20134035.","DOI":"10.1182\/blood.V94.12.4029"},{"key":"2019111702205070300_R20","doi-asserted-by":"crossref","unstructured":"Torres HA, Kontoyiannis DP, Bodey G, et al. Gastrointestinal cytomegalovirus disease in patients with cancer: A two-decade experience in a tertiary care cancer center. Eur J Cancer. 2005;41:2268\u20132279.","DOI":"10.1016\/j.ejca.2005.07.011"},{"key":"2019111702205070300_R21","doi-asserted-by":"crossref","unstructured":"Chemaly RF, Torres HA, Hachem RY, et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer. 2005;104:1213\u20131220.","DOI":"10.1002\/cncr.21294"},{"key":"2019111702205070300_R22","doi-asserted-by":"crossref","unstructured":"Nquyen Q, Estey E, Raad I, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis. 2001;32:539\u2013545.","DOI":"10.1086\/318721"},{"key":"2019111702205070300_R23","doi-asserted-by":"crossref","unstructured":"Boeckh M, Gallez-Hawkins GM, Meyerson D, et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia and viral culture. Transplantation. 1997;64:108\u2013113.","DOI":"10.1097\/00007890-199707150-00020"},{"key":"2019111702205070300_R24","doi-asserted-by":"crossref","unstructured":"Ljungman P, Reusser P, de la Camara R, et al. Management of CMV Infections: Recommendations from the Infectious Diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075\u20131081.","DOI":"10.1038\/sj.bmt.1704505"},{"key":"2019111702205070300_R25","unstructured":"Foulongne V, Turriere C, Diafouka F, Abraham B, Lastere S, Segondy M. Ganciclovir resistance mutations in UL97 and UL54 genes of human cytomegalovirus isolates resistant to ganciclovir. Acta Virologica. 2004;48:51\u201355."},{"key":"2019111702205070300_R26","doi-asserted-by":"crossref","unstructured":"Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407\u2013414.","DOI":"10.1182\/blood-2002-03-0993"},{"key":"2019111702205070300_R27","doi-asserted-by":"crossref","unstructured":"Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation; impact of host factors, drug therapy and subclinical reactivation. Blood. 2003;102:3060\u20133067.","DOI":"10.1182\/blood-2002-11-3472"},{"key":"2019111702205070300_R28","doi-asserted-by":"crossref","unstructured":"Wilson DJ, Baden LR, Gabriel DA, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant. 2006;12:635\u2013640.","DOI":"10.1016\/j.bbmt.2005.12.038"},{"key":"2019111702205070300_R29","doi-asserted-by":"crossref","unstructured":"Ayala E, Green J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:851\u2013856.","DOI":"10.1038\/sj.bmt.1705341"},{"key":"2019111702205070300_R30","doi-asserted-by":"crossref","unstructured":"Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173\u2013178.","DOI":"10.7326\/0003-4819-118-3-199302010-00003"},{"key":"2019111702205070300_R31","doi-asserted-by":"crossref","unstructured":"Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failure in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757\u2013763.","DOI":"10.1038\/sj.bmt.1702226"},{"key":"2019111702205070300_R32","doi-asserted-by":"crossref","unstructured":"Clark DA. Human herpesvirus 6. Rev Med Virol. 2000;10:155\u2013173.","DOI":"10.1002\/(SICI)1099-1654(200005\/06)10:3<155::AID-RMV277>3.0.CO;2-6"},{"key":"2019111702205070300_R33","doi-asserted-by":"crossref","unstructured":"Zerr DM, Gooley TA, Yeung L, et al. Clinical outcomes of human herpesvirus 6 reactivation after stem cell transplantation. Clin Infect Dis. 2005;40:932\u2013940.","DOI":"10.1086\/428060"},{"key":"2019111702205070300_R34","doi-asserted-by":"crossref","unstructured":"Cone RW, Huang ML, Corey L, et al. Human herpesvirus 6 infection after bone marrow transplantation: clinical and virological manifestations. J Infect Dis. 1999;179:311\u2013318.","DOI":"10.1086\/314581"},{"key":"2019111702205070300_R35","doi-asserted-by":"crossref","unstructured":"Kojaoghlanian T, Flomberg P, Horowitz MS. The impact of adenovirus on the immunosuppressed host. Rev Med Virol. 2003;13:155\u2013171.","DOI":"10.1002\/rmv.386"},{"key":"2019111702205070300_R36","unstructured":"Bruno B, Gooley T, Hackman RC, et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant. 2004;77:1049\u20131057."},{"key":"2019111702205070300_R37","doi-asserted-by":"crossref","unstructured":"Runde V, Ross S, Trenschel R, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multicenter surveillance study. Bone Marrow Transplant. 2001;28:51\u201357.","DOI":"10.1038\/sj.bmt.1703083"},{"key":"2019111702205070300_R38","doi-asserted-by":"crossref","unstructured":"Fianchi L, Scardocci A, Cattani P, et al. Adenovirus meningoencephalitis in a patient with large B-cell lymphoma. Ann Hematol. 2003;82:313\u2013315.","DOI":"10.1007\/s00277-003-0637-x"},{"key":"2019111702205070300_R39","doi-asserted-by":"crossref","unstructured":"Kaur B, Gottardo GG, Keil AD, Hallam LA, Baker DL. A rare case of adenoviral fulminant hepatic necrosis after chemotherapy. Pediatr Hematol Oncol. 2002;19(5):361\u2013371.","DOI":"10.1080\/08880010290057390"},{"key":"2019111702205070300_R40","doi-asserted-by":"crossref","unstructured":"Lion T, Baumgartiner R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102;1114\u20131120.","DOI":"10.1182\/blood-2002-07-2152"},{"key":"2019111702205070300_R41","doi-asserted-by":"crossref","unstructured":"Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infection after allogeneic hematopoietic stem-cell transplantation. Bone Marrow Transplant. 2003;31:481\u2013486.","DOI":"10.1038\/sj.bmt.1703798"},{"key":"2019111702205070300_R42","doi-asserted-by":"crossref","unstructured":"Randhawa PS, Demetris AJ, Nephropathy due to polyomavirus type BK. N Engl J Med. 2000;342:1361\u20131363.","DOI":"10.1056\/NEJM200005043421809"},{"key":"2019111702205070300_R43","doi-asserted-by":"crossref","unstructured":"Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005;106:1130\u20131132.","DOI":"10.1182\/blood-2004-12-4988"},{"key":"2019111702205070300_R44","doi-asserted-by":"crossref","unstructured":"Erard V, Storer B, Corey L, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors and association with post engraftment hemorrhagic cystitis. CID. 2004;39:1381\u20131865.","DOI":"10.1086\/426140"},{"key":"2019111702205070300_R45","doi-asserted-by":"crossref","unstructured":"Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med. 2005;352:1157\u20131158.","DOI":"10.1056\/NEJM200503173521125"},{"key":"2019111702205070300_R46","doi-asserted-by":"crossref","unstructured":"Bridges B, Donegan S, Badros A, et al. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol. 2006;81(7):535\u2013537.","DOI":"10.1002\/ajh.20567"},{"key":"2019111702205070300_R47","doi-asserted-by":"crossref","unstructured":"Englund J. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol Blood Marrow Transplant. 2001;7:25\u201345.","DOI":"10.1053\/bbmt.2001.v7.pm11777101"},{"key":"2019111702205070300_R48","doi-asserted-by":"crossref","unstructured":"Nichols GW, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center Experience. Biol Blood Marrow Transplant. 2001;7:11S\u201315S","DOI":"10.1053\/bbmt.2001.v7.pm11777098"},{"key":"2019111702205070300_R49","doi-asserted-by":"crossref","unstructured":"Peck AJ, Corey L, Boeckh M. Pre-transplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. CID. 2004;39:673\u2013680.","DOI":"10.1086\/422994"},{"key":"2019111702205070300_R50","doi-asserted-by":"crossref","unstructured":"Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443\u2013450.","DOI":"10.1056\/NEJMoa025472"},{"key":"2019111702205070300_R51","doi-asserted-by":"crossref","unstructured":"Englund J, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:374\u2013375.","DOI":"10.7326\/0003-4819-144-5-200603070-00010"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/368\/1091651\/368_374ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/368\/1091651\/368_374ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T15:57:58Z","timestamp":1683647878000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/368\/19807\/Viral-Infections-in-Patients-with-Hematological"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.368","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}